SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study

BACKGROUND: Long-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. In the present prospective study, we aimed to evaluate severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody response with BBIBP-CorV...

Descripción completa

Detalles Bibliográficos
Autores principales: Safarnezhad Tameshkel, Fahimeh, Abedin Dargoush, Shabnam, Amirkalali, Bahareh, Javadi, Saeedeh, Ghiaseddin, Ali, Alimohamadi, Yousef, Basi, Ali, Jamshidi Makiani, Mahin, Zamani, Farhad, Karbalaie Niya, Mohammad Hadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893850/
https://www.ncbi.nlm.nih.gov/pubmed/36743671
http://dx.doi.org/10.3389/fmed.2022.1095194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893850/
https://www.ncbi.nlm.nih.gov/pubmed/36743671
http://dx.doi.org/10.3389/fmed.2022.1095194

Ejemplares similares